22.34
price down icon2.29%   -0.59
 
loading
Novocure Ltd stock is traded at $22.34, with a volume of 305.68K. It is down -2.29% in the last 24 hours and down -22.77% over the past month. NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$22.93
Open:
$22.81
24h Volume:
305.68K
Relative Volume:
0.27
Market Cap:
$2.48B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-15.96
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-8.63%
1M Performance:
-22.77%
6M Performance:
+16.63%
1Y Performance:
+49.76%
1-Day Range:
Value
$22.31
$23.18
1-Week Range:
Value
$22.31
$24.73
52-Week Range:
Value
$11.70
$34.13

Novocure Ltd Stock (NVCR) Company Profile

Name
Name
Novocure Ltd
Name
Phone
44 (0)15 3475 6700
Name
Address
NO. 4 THE FORUM, ST. HELIER
Name
Employee
1,453
Name
Twitter
@novocure
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
NVCR's Discussions on Twitter

Compare NVCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
NVCR
Novocure Ltd
22.34 2.48B 577.74M -149.78M -78.21M -1.40
Medical Devices icon
ABT
Abbott Laboratories
128.84 222.39B 41.95B 13.40B 6.49B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
105.39 154.78B 15.91B 1.79B 1.89B 1.21
Medical Devices icon
SYK
Stryker Corp
391.86 150.99B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
89.85 116.46B 33.00B 4.29B 5.50B 3.27
Medical Devices icon
EW
Edwards Lifesciences Corp
71.04 41.87B 6.60B 4.16B 490.10M 6.93

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Upgrade Evercore ISI In-line → Outperform
Oct-16-24 Upgrade H.C. Wainwright Neutral → Buy
Nov-20-23 Resumed JP Morgan Neutral
Aug-28-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-08-23 Upgrade Piper Sandler Neutral → Overweight
Aug-04-23 Initiated SVB Securities Outperform
Jul-31-23 Upgrade Evercore ISI Underperform → In-line
Jun-07-23 Upgrade Wedbush Underperform → Neutral
May-16-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-17-23 Downgrade JP Morgan Neutral → Underweight
Jan-06-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-05-23 Reiterated H.C. Wainwright Buy
Nov-29-22 Upgrade Wells Fargo Equal Weight → Overweight
Oct-24-22 Downgrade Piper Sandler Overweight → Neutral
Jul-05-22 Downgrade Evercore ISI In-line → Underperform
May-16-22 Initiated H.C. Wainwright Buy
Feb-08-22 Initiated Loop Capital Buy
Feb-02-22 Upgrade Oppenheimer Perform → Outperform
Jan-20-22 Upgrade Truist Hold → Buy
Jan-03-22 Upgrade Evercore ISI Underperform → In-line
Jul-01-21 Downgrade Mizuho Buy → Neutral
Apr-14-21 Downgrade Wedbush Neutral → Underperform
Jan-25-21 Reiterated Piper Sandler Overweight
Sep-23-20 Initiated Northland Capital Outperform
Sep-18-20 Downgrade Wells Fargo Overweight → Equal Weight
Sep-17-20 Downgrade Truist Buy → Hold
Jun-01-20 Resumed Oppenheimer Perform
May-01-20 Downgrade Oppenheimer Outperform → Perform
Apr-09-20 Downgrade Evercore ISI In-line → Underperform
Mar-05-20 Upgrade Wells Fargo Equal Weight → Overweight
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-19 Upgrade SunTrust Hold → Buy
Jul-26-19 Downgrade JP Morgan Overweight → Neutral
Jul-26-19 Downgrade Wedbush Outperform → Neutral
Mar-20-19 Initiated SunTrust Hold
Nov-02-18 Downgrade Wells Fargo Outperform → Market Perform
Jul-16-18 Initiated Evercore ISI Outperform
Apr-18-18 Reiterated Mizuho Buy
Feb-23-18 Reiterated Mizuho Buy
May-24-17 Upgrade Wells Fargo Market Perform → Outperform
Jul-29-16 Reiterated Wedbush Outperform
Jan-19-16 Initiated Barclays Underweight
Dec-02-15 Initiated Deutsche Bank Hold
View All

Novocure Ltd Stock (NVCR) Latest News

pulisher
Feb 06, 2025

What was NovoCure Ltd (NVCR)’s performance in the last session? - US Post News

Feb 06, 2025
pulisher
Feb 05, 2025

Evercore ISI Upgrades NovoCure Ltd (NVCR) to an Outperform from an In-line - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Financial Snapshot: Analyzing Spectral AI Inc (MDAI)’s Key Ratio Metrics - The Dwinnex

Feb 05, 2025
pulisher
Feb 05, 2025

Ratio Examination: NovoCure Ltd (NVCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 05, 2025
pulisher
Feb 01, 2025

Exchange Traded Concepts LLC Has $859,000 Stock Holdings in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

NovoCure Ltd (NVCR) Should Be Considered Now, Despite A Loss Of -28.16% From High - Stocks Register

Feb 01, 2025
pulisher
Jan 31, 2025

Nisa Investment Advisors LLC Grows Position in NovoCure Limited (NASDAQ:NVCR) - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' - Benzinga

Jan 30, 2025
pulisher
Jan 30, 2025

Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $32.67 - MarketBeat

Jan 30, 2025
pulisher
Jan 30, 2025

NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Jan 30, 2025
pulisher
Jan 25, 2025

NovoCure Ltd (NASDAQ: NVCR): Overvalued In Comparison To Others? - Stocks Register

Jan 25, 2025
pulisher
Jan 25, 2025

NovoCure (NASDAQ:NVCR) Stock Price Crosses Above 50-Day Moving AverageWhat's Next? - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Novocure Ltd. to Host Earnings Call - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 22, 2025

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Yahoo Finance

Jan 22, 2025
pulisher
Jan 21, 2025

Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain - Yahoo Finance

Jan 21, 2025
pulisher
Jan 21, 2025

Novocure gets approval for rooftop penthouse at downtown Portsmouth headquarters - AOL

Jan 21, 2025
pulisher
Jan 18, 2025

FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

NovoCure’s (NVCR) Buy Rating Reiterated at HC Wainwright - Defense World

Jan 17, 2025
pulisher
Jan 17, 2025

HC Wainwright Forecasts NovoCure FY2029 Earnings - Defense World

Jan 17, 2025
pulisher
Jan 17, 2025

Wedbush Has Positive Outlook of NovoCure FY2024 Earnings - Defense World

Jan 17, 2025
pulisher
Jan 16, 2025

HC Wainwright Predicts NovoCure FY2029 Earnings - MarketBeat

Jan 16, 2025
pulisher
Jan 16, 2025

Wedbush Comments on NovoCure's FY2024 Earnings (NASDAQ:NVCR) - MarketBeat

Jan 16, 2025
pulisher
Jan 16, 2025

Novocure's COO Mukund Paravasthu sells $57,906 in shares By Investing.com - Investing.com South Africa

Jan 16, 2025
pulisher
Jan 15, 2025

Novocure's COO Mukund Paravasthu sells $57,906 in shares - Investing.com India

Jan 15, 2025
pulisher
Jan 15, 2025

NovoCure Ltd (NVCR) Shares Down 3.67% on Jan 14 - GuruFocus.com

Jan 15, 2025
pulisher
Jan 14, 2025

NovoCure (NASDAQ:NVCR) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 14, 2025

Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) - Benzinga

Jan 14, 2025
pulisher
Jan 14, 2025

NovoCure’s (NVCR) Neutral Rating Reaffirmed at Wedbush - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

NovoCure's (NVCR) Neutral Rating Reiterated at Wedbush - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Is Now The Time To Buy NovoCure Ltd (NASDAQ: NVCR) Stock? - Stocks Register

Jan 13, 2025
pulisher
Jan 13, 2025

Novocure reports revenue growth, FDA approvals in 2024 - Investing.com India

Jan 13, 2025
pulisher
Jan 13, 2025

Novocure Reports Strong 19% Revenue Growth, Hits $605M as Cancer Treatment Platform Expands - StockTitan

Jan 13, 2025
pulisher
Jan 08, 2025

Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 97% gain - Simply Wall St

Jan 08, 2025
pulisher
Jan 05, 2025

NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Versant Capital Management Inc - Defense World

Jan 05, 2025
pulisher
Jan 05, 2025

NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Average PT from Brokerages - MarketBeat

Jan 05, 2025
pulisher
Jan 05, 2025

NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jan 05, 2025
pulisher
Jan 03, 2025

Novocure CEO to Present at J.P. Morgan Healthcare Conference, Announces Investor Meetings - StockTitan

Jan 03, 2025
pulisher
Jan 03, 2025

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance

Jan 03, 2025
pulisher
Dec 26, 2024

NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Franklin Resources Inc. - MarketBeat

Dec 26, 2024
pulisher
Dec 25, 2024

Geode Capital Management LLC Acquires 29,871 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World

Dec 25, 2024
pulisher
Dec 18, 2024

NovoCure (NASDAQ:NVCR) Reaches New 12-Month HighShould You Buy? - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Research Analysts’ Recent Ratings Updates for NovoCure (NVCR) - Defense World

Dec 17, 2024
pulisher
Dec 16, 2024

Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges - Investing.com Australia

Dec 16, 2024
pulisher
Dec 16, 2024

Tumor Treating Fields Market Growth in Future Scope 2024-2031 | Novocure GmbH and Zai Lab - openPR

Dec 16, 2024
pulisher
Dec 15, 2024

Novocure's SWOT analysis: oncology med-tech firm's stock faces growth challenges By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 15, 2024

NovoCure (NASDAQ:NVCR) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Dec 15, 2024
pulisher
Dec 15, 2024

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? - Benzinga

Dec 15, 2024
pulisher
Dec 14, 2024

Novocure Stock Hits 52-Week High at $32.65 Amidst Strong Yearly Growth - Investing.com Australia

Dec 14, 2024
pulisher
Dec 14, 2024

NovoCure (NASDAQ:NVCR) Shares Gap Up on Analyst Upgrade - MarketBeat

Dec 14, 2024
pulisher
Dec 14, 2024

Novocure price target raised to $42 from $28 at Piper Sandler - Yahoo Finance

Dec 14, 2024

Novocure Ltd Stock (NVCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices ZBH
$100.83
price down icon 1.81%
medical_devices STE
$222.21
price down icon 1.44%
medical_devices PHG
$27.32
price down icon 0.54%
$88.19
price down icon 0.44%
$87.85
price down icon 0.85%
medical_devices EW
$70.98
price down icon 0.06%
Cap:     |  Volume (24h):